We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly.
News
- innoVation Series December 22 / January 23With the New Year we are focussing on the importance of human iPSC-derived cardiomyocyte beat rate […]
- Meet us at the 62nd Society of Toxicology Annual Meeting in Nashville, USAThe SOT conference will take place in March 19 – 23, 2023. Keep an eye out for more […]
- innoVation Series October / November 2022The October issue of the innoVation series is a special workshop report of the FDA (Pang et al., […]
- Post date August 20, 2020